Učitavanje...
An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer
BACKGROUND: Combining anti-cancer therapies with orthogonal modes of action, such as direct cytotoxicity and immunostimulatory, hold promise for expanding clinical benefit to patients with metastatic disease. For instance, a chemotherapy agent Oxaliplatin (OXP) in combination with Interleukin-12 (IL...
Spremljeno u:
| Izdano u: | BMC Cancer |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6950805/ https://ncbi.nlm.nih.gov/pubmed/31914948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6500-9 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|